Emil Zhang

October 30, 2022

Emil Zhang is the Director of European IPR Department, Huawei, where he has specialized in IP, contract, litigation, and legal management for many years. He has participated in high profile company-level litigations, including EU trade defense investigation (anti-dumping, anti-subsidies, safeguard) and major patent litigation. He has led the company’s patent infringement assertions across the world as well as company-level cooperation projects with major industrial peers, customers, and suppliers. He focuses now more on IP related litigation, patent licensing program and trade defense investigations.

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor

U.S. Universities: Engines of Economic Growth

November 13, 2025

By Sujai Shivakumar, Charles Wessner, Chris Borges, and Shruti Sharma Universities are among the United States’ most enduring sources of competitive advantage and a key pillar of the nation’s innovation system. Home to more than 35 of the world’s top 100 research universities, the United States owes many of its most